YASEMİN ÖZ, Filiz AKŞİT, Müge ASLAN, NİLGÜN KAŞİFOĞLU, Nuri KİRAZ

Klinik Aspergıllus izolatları: Tür dağılımı ve antifungal duyarlılık sonuçlarının değerlendirilmesi

Aspergillus türleri tüm dünyada yaygın olarak bulunmakla birlikte, özellikle immündüşkün hastalar için invazif Aspergillus infeksiyonları önemli bir problemdir. Bu çalışmada, hastanemizde izole edilmiş Aspergillus izolatlarının tür dağılımı ve antifungal duyarlılığı analiz edilmiştir. Toplam 110 izolat analize alınmış ve bunların % 60ı Aspergillus fumigatus, % 21i Aspergillus niger, % 9u ise Aspergillus flavus olarak tanımlanmıştır. İzolatların % 54ü Göğüs Hastalıkları Servisi hastalarından ve % 75i solunum yolu örneklerinden elde edilmiştir. Antifungal duyarlılık testi için E-test yöntemi kullanılmış ve minimal inhibitör konsantrasyon aralıkları amfoterisin B için 0.012-32 μg/ml, itrakonazol için 0.008-128 μg/ml ve vorikonazol için 0.023-8 μg/ml olarak bulunmuştur. Test edilen üç antifungal arasında en etkilisi vorikonazol olmuştur. Sonuç olarak invazif aspergillozların en sık etkeni A.fumigatustur ve vorikonazol amfoterisin Bye güvenilir bir alternatif olabilir.

Clinical Aspergillus isolates: Evaluation of species distribution and antifungal susceptibility results

Although Aspergillus spp. are widespread in the world, invasive Aspergillus infections are important problems for especially immunocompromised patients. In this study, the species distribution and antifungal susceptibility test results of Aspergillus spp. isolated in our hospital were analyzed. A total of 110 isolates were included and 60 % of them were Aspergillus fumigatus, 21 % Aspergillus niger and 9 % Aspergillus flavus. Of the isolates, 54 % were obtained from the patients of Department of Chest Diseases and 75 % were isolated from respiratory tract specimens. E-test method was performed for antifungal susceptibility testing and minimal inhibitory concentration ranges were found as 0.012-32 μg/ml for amphotericin B, 0.008-128 μg/ml for itraconazole and 0.023-8 μg/ml for voriconazole. The most potent agent was voriconazole among three antifungals tested. Consequently, the most common agent of invasive aspergillosis is A. fumigatus and voriconazole may be a reliable alternative to amphotericin B.

PDF

___

1. Aneja KR, Sharma C, Joshi R. Fungal infection of the ear: a common problem in the northeastern part of Haryana, Int J Pediatr Otorhinolaryngol 2010; 74(6):604-7. http://dx.doi.org/10.1016/j.ijporl.2010.03.001 PMid:20347163
2. Bodey G, Bueltmann B, Duguid W et al. Fungal infections in cancer patients: an international autopsy study, Eur J Clin Microbiol Infect Dis 1992; 11(2):99-109. PubMedPMID:1396746
3. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Monzon A, Buitrago MJ, Rodriguez-Tudela JL. Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds, Antimicrob Agents Chemother 2009;53(5):2192-5. http://dx.doi.org/10.1128/AAC.01543-08 PMid:19223630 PMCid:2681500
4. Değerli K, Akçalı S, Sezgin C, Ünlü H, Özbak-kaloğlu B. Manisa ve çevresinde soyutlanan otomikoz etkenleri, İnfeksiyon Derg 2002;16(2):211-3. http://infeksiyon.dergisi.org/text.php3?id=179
5. Jia X, Liang Q, Chi F, Cao W. Otomycosis in Shanghai: aetiology, clinical features and therapy, Mycoses 2011;doi: 10.1111/j.1439-507.2011.02132.x. PubMed PMID: 21999222
6. Krishnan S, Manavathu EK, Chandrasekar PH. Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance, Mycoses 2009;52(3):206-22. http://dx.doi.org/10.1111/j.1439-0507.2008.01642.x PMid:19207851
7. Lass-Flörl C, Perkhofer S. In vitro susceptibility-testing in Aspergillus species, Mycoses 2008; 51(5):437-46. http://dx.doi.org/10.1111/j.1439-0507.2008.01510.x PMid:18422914
8. Ozcan KM, Ozcan M, Karaarslan A Karaarslan F. Otomycosis in Turkey: predisposing factors, aetiology and therapy, J Laryngol Otol 2003;117(1):39-42. PubMed PMID: 12590854 http://dx.doi.org/10.1258/002221503321046621
9. Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000, Antimicrob Agents Chemother 2002;46(4):1032-7. http://dx.doi.org/10.1128/AAC.46.4.1032-1037.2002 PMid:11897586 PMCid:127116
10. Pfaller MA, Messer SA, Mills K, Bolmström A. In vitro susceptibility testing of filamentous fungi: comparison of E test and reference microdilution methods for determining itraconazole MICs, J Clin Microbiol 2000;38(9):3359-61. PubMedPMID: 10970383; PubMed Central PMCID: PMC87386.
11. Rolston K. Overview of systemic fungal infections, Oncology (Williston Park) 2001;15(11 Suppl 9):11-4. PubMed PMID: 11757845
12. Rudramurthy SM, Chakrabarti A, Geertsen E, Mouton JW, Meis JF. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Sus-ceptibility Testing, Diagn Microbiol Infect Dis 2011;71(4):370-7. http://dx.doi.org/10.1016/j.diagmicrobio.2011. 08.006 PMid:21937186
13. Schuster E, Dunn-Coleman N, Frisvad JC, Van Dijck PW. On the safety of Aspergillus niger-a review, Appl Microbiol Biotechnol 2002;59(4-5):426-35. http://dx.doi.org/10.1007/s00253-002-1032-6 PMid:12172605
14. Szekely A, Johnson E, Warnock D. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of moulds, J Clin Microbiol 1999;37(5):1480-3. PMid:10203509 PMCid:84808